PMID- 25301760
OWN - NLM
STAT- MEDLINE
DCOM- 20160407
LR  - 20221208
IS  - 1873-7560 (Electronic)
IS  - 0302-2838 (Linking)
VI  - 67
IP  - 6
DP  - 2015 Jun
TI  - Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": 
      Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, 
      CRUK/06/019).
PG  - 1028-1038
LID - S0302-2838(14)00969-5 [pii]
LID - 10.1016/j.eururo.2014.09.032 [doi]
AB  - BACKGROUND: Prostate cancer (PCa) is the second most common disease among men 
      worldwide. It is important to know survival outcomes and prognostic factors for 
      this disease. Recruitment for the largest therapeutic randomised controlled trial 
      in PCa--the Systemic Therapy in Advancing or Metastatic Prostate Cancer: 
      Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial 
      (STAMPEDE)--includes men with newly diagnosed metastatic PCa who are commencing 
      long-term androgen deprivation therapy (ADT); the control arm provides valuable 
      data for a prospective cohort. OBJECTIVE: Describe survival outcomes, along with 
      current treatment standards and factors associated with prognosis, to inform 
      future trial design in this patient group. DESIGN, SETTING, AND PARTICIPANTS: 
      STAMPEDE trial control arm comprising men newly diagnosed with M1 disease who 
      were recruited between October 2005 and January 2014. OUTCOME MEASUREMENTS AND 
      STATISTICAL ANALYSIS: Overall survival (OS) and failure-free survival (FFS) were 
      reported by primary disease characteristics using Kaplan-Meier methods. Hazard 
      ratios and 95% confidence intervals (CIs) were derived from multivariate Cox 
      models. RESULTS AND LIMITATIONS: A cohort of 917 men with newly diagnosed M1 
      disease was recruited to the control arm in the specified interval. Median 
      follow-up was 20 mo. Median age at randomisation was 66 yr (interquartile range 
      [IQR]: 61-71), and median prostate-specific antigen level was 112 ng/ml (IQR: 
      34-373). Most men (n=574; 62%) had bone-only metastases, whereas 237 (26%) had 
      both bone and soft tissue metastases; soft tissue metastasis was found mainly in 
      distant lymph nodes. There were 238 deaths, 202 (85%) from PCa. Median FFS was 11 
      mo; 2-yr FFS was 29% (95% CI, 25-33). Median OS was 42 mo; 2-yr OS was 72% (95% 
      CI, 68-76). Survival time was influenced by performance status, age, Gleason 
      score, and metastases distribution. Median survival after FFS event was 22 mo. 
      Trial eligibility criteria meant men were younger and fitter than general PCa 
      population. CONCLUSIONS: Survival remains disappointing in men presenting with M1 
      disease who are started on only long-term ADT, despite active treatments being 
      available at first failure of ADT. Importantly, men with M1 disease now spend the 
      majority of their remaining life in a state of castration-resistant relapse. 
      PATIENT SUMMARY: Results from this control arm cohort found survival is 
      relatively short and highly influenced by patient age, fitness, and where 
      prostate cancer has spread in the body.
CI  - Copyright (c) 2014 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - James, Nicholas David
AU  - James ND
AD  - University of Warwick, Coventry, UK. Electronic address: N.D.James@warwick.ac.uk.
FAU - Spears, Melissa R
AU  - Spears MR
AD  - Medical Research Council Clinical Trials Unit at University College London, 
      London, UK.
FAU - Clarke, Noel W
AU  - Clarke NW
AD  - Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.
FAU - Dearnaley, David P
AU  - Dearnaley DP
AD  - Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, 
      London and Sutton, UK.
FAU - De Bono, Johann S
AU  - De Bono JS
AD  - Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, 
      London and Sutton, UK.
FAU - Gale, Joanna
AU  - Gale J
AD  - Queen Alexandra Hospital, Portsmouth, UK.
FAU - Hetherington, John
AU  - Hetherington J
AD  - Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
FAU - Hoskin, Peter J
AU  - Hoskin PJ
AD  - Mount Vernon Hospital, Northwood, Middlesex, UK.
FAU - Jones, Robert J
AU  - Jones RJ
AD  - University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
FAU - Laing, Robert
AU  - Laing R
AD  - Royal Surrey County Hospital, Guildford, UK.
FAU - Lester, Jason F
AU  - Lester JF
AD  - Velindre Hospital, Cardiff, UK.
FAU - McLaren, Duncan
AU  - McLaren D
AD  - Western General Hospital, Edinburgh, UK.
FAU - Parker, Christopher C
AU  - Parker CC
AD  - Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, 
      London and Sutton, UK.
FAU - Parmar, Mahesh K B
AU  - Parmar MKB
AD  - Medical Research Council Clinical Trials Unit at University College London, 
      London, UK.
FAU - Ritchie, Alastair W S
AU  - Ritchie AWS
AD  - Medical Research Council Clinical Trials Unit at University College London, 
      London, UK.
FAU - Russell, J Martin
AU  - Russell JM
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
FAU - Strebel, Rato T
AU  - Strebel RT
AD  - Kantonsspital Graubunden, Chur, Switzerland.
FAU - Thalmann, George N
AU  - Thalmann GN
AD  - Department of Urology, University Hospital, Bern, Switzerland.
FAU - Mason, Malcolm D
AU  - Mason MD
AD  - Velindre Hospital, Cardiff, UK.
FAU - Sydes, Matthew R
AU  - Sydes MR
AD  - Medical Research Council Clinical Trials Unit at University College London, 
      London, UK.
LA  - eng
GR  - MC_U122861330/MRC_/Medical Research Council/United Kingdom
GR  - 12459/CRUK_/Cancer Research UK/United Kingdom
GR  - MC_UU_12023/25/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12023/6/MRC_/Medical Research Council/United Kingdom
GR  - 3804/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141006
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Androgen Antagonists)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
CIN - Eur Urol. 2015 Jun;67(6):1039-41. PMID: 25544634
CIN - J Urol. 2016 Feb;195(2):350. PMID: 26852973
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Antagonists/*therapeutic use
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Docetaxel
MH  - Early Detection of Cancer/mortality
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis/diagnosis/pathology/*therapy
MH  - Physical Fitness
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/diagnosis/*drug therapy/mortality/pathology
MH  - Risk Factors
MH  - Taxoids/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Control arm cohort
OT  - Hormone-naive
OT  - Metastatic
OT  - Natural history
OT  - Prognostic factors
OT  - Prospective data
OT  - Prostate cancer
OT  - Survival
OT  - Time to progression
EDAT- 2014/10/11 06:00
MHDA- 2016/04/08 06:00
CRDT- 2014/10/11 06:00
PHST- 2014/07/23 00:00 [received]
PHST- 2014/09/19 00:00 [accepted]
PHST- 2014/10/11 06:00 [entrez]
PHST- 2014/10/11 06:00 [pubmed]
PHST- 2016/04/08 06:00 [medline]
AID - S0302-2838(14)00969-5 [pii]
AID - 10.1016/j.eururo.2014.09.032 [doi]
PST - ppublish
SO  - Eur Urol. 2015 Jun;67(6):1028-1038. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 
      Oct 6.